A functional CRISPR/Cas9 screen identifies kinases that modulate FGFR inhibitor response in gastric cancer.

Some gastric cancers have FGFR2 amplifications, making them sensitive to FGFR inhibitors. However, cancer cells inevitably develop resistance despite initial response. The underlying resistance mechanism to FGFR inhibition is unclear.